

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Graham P. Allaway, et al.
Serial No.: Not Yet Known (continuation of U.S. Serial No.
08/831,823, filed April 2, 1997)
Filed : June 25, 2001
For : METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+
CELLS

1185 Avenue of the Americas
New York, New York 10036
June 25, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Applications

SIR:

PRELIMINARY AMENDMENT

Please amend the subject application as follows:

In the specification:

On page 1, lines 1-5, please delete the paragraph which begins "This application claims priority of U.S. Provisional" and insert the following paragraph:

--This application is a continuation of U.S. 08/831,823, filed April 2, 1997, which claims priority of U.S. Provisional Application No. 60/019,715, filed June 14, 1996, and U.S. Provisional Application No. 60/014,532, filed April 2, 1996, the contents of which are incorporated by reference into this application.--

In the claims:

Please cancel claims 1-50 without prejudice or disclaimer to

Applicants : Graham P. Allaway, et al.
U.S. Serial No : Not Yet Known
Filed : June 25, 2001
Page 2

applicants' right to pursue the subject matter of these claims in a later-filed application and please add new claims 51-56 as follows:

- 51. (New) An antibody or portion of an antibody capable of binding to a chemokine receptor on the surface of a CD4+ cell.--
- 52. (New) The antibody or portion of an antibody capable of binding to a CCR5 chemokine receptor on the surface of a CD4+ cell.--
- 53. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a PM-1 cell.--
- 54. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a primary CD4+ T-cell.--
- 55. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the CD4+ cell is a PMBC cell.--
- 56. (New) The antibody or portion of an antibody of claim 51 or 52, wherein the antibody is a monoclonal antibody.--

Remarks

Claims 1-50 are pending in the subject application. Applicants have hereinabove canceled claims 1-50 without prejudice or disclaimer to their right to pursue the subject matter of these claims in a later-filed application and added new claims 51-56. Support for newly added claims 51-56 may be found inter alia in the specification as follows: claim 51: page 4, lines 22-23; page 16, line 34; claim 52: page 11, lines 21-23; claim 53: page 26, table

Applicants : Graham P. Allaway, et al.
U.S. Serial No : Not Yet Known
Filed : June 25, 2001
Page 3

1; claim 54: page 30, lines 17-18; claim 55: page 33, lines 5-6;
claim 56: page 28, line 25. This amendment does not involve any
issue of new matter. Therefore, entry of this amendment is
respectfully requested, such that claims 51-56 will be pending.

If a telephone interview would be of assistance in advancing
prosecution of the subject application, applicants' undersigned
attorneys invite the Examiner to telephone either of them at the
number provided below.

No fee, other than the enclosed \$490.00 filing fee, is deemed
necessary in connection with the filing of this Preliminary
Amendment. However, if any additional fee is required,
authorization is hereby given to charge the amount of any such fee
to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Spencer H. Schneider
Registration No. 45,923
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400